(Bourcier.com) – Valneva Will participate in a UK government-funded clinical study launched today to investigate various Kovid-19 vaccines that can be used as boosters. The Cove-Boost study, conducted by Southampton University Hospital NHS Foundation Trust, will study seven vaccines, including the inactive Valneva VLA 2001 vaccine, for use as a booster. This test will be the first in the world to provide the necessary data on the effectiveness of boosters with each vaccine to protect against viruses.
These vaccines will be given at least three months after vaccination with a second dose as part of an ongoing vaccination program in the UK. Each volunteer will be given a booster and may be of a different brand from the initial vaccine. The test will also include a control group.
The first results of the study, expected in September, will help the British Committee for Immunization and Immunization (JCVI) decide whether a potential recall program is put in place as soon as this fall, aimed at ensuring that the UK The most vulnerable of people get the best possible protection during the winter months.
Parallel to the Cove-Boost study, the Valneva Group will continue to work on the critical Phase 3 ‘Cove-Comparison’ study (VLA2001-301) launched in April 2021. This study compares the SARS vaccine candidate -COV-2. Valneva, VLA2001, for the Vaxzevria vaccine, which has already received conditional marketing authorization. Recruitment for this trial is currently ongoing, conducted in the UK and supported by the UK National Institutes for Health (NIH) research body. Subject to the positive results of Phase 3, Valneva hopes to submit a marketing authorization application during the fall.
© 2011, Boursier.com